Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 |
| clinicaltrials |
| NCT03007823 | High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02045368 | Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | completed | Phase 1 | 92 | IGF Oncology, LLCINDUSTRY | 1 | Aug 22, 2019 | clinicaltrials |
| NCT00571116 | Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy | terminated | Phase 1 | 9 | University of California, IrvineOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Aprea TherapeuticsINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT01271803 | A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 131 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2019 | clinicaltrials |
| NCT01639911 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | completed | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT02891616 | 18F-FLT PET Imaging in Patients With Advanced Melanoma | terminated | Phase 1 | 4 | Washington University School of MedicineOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT01996202 | A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00438009 | A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) | completed | Phase 1 | 9 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)(PSX-X04) | completed | Phase 1 | 8 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT00235482 | Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)(PXS-X02) | completed | Phase 1 | 3 | ViralyticsINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01137006 | An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma | completed | Phase 1 | 27 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00301067 | Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT01910181 | A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | completed | Phase 1 | 46 | Hoffmann-La RocheINDUSTRY | 1 | May 29, 2019 | clinicaltrials |
| NCT01017185 | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions | completed | Phase 1 | 28 | Takara Bio Inc.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT01603212 | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | completed | Phase 1 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02027961 | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | completed | Phase 1 | 68 | MedImmune LLCINDUSTRY | 4 | May 17, 2019 | clinicaltrials |
| NCT03472027 | Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma | completed | Phase 1 | 15 | BiocadINDUSTRY | 1 | May 9, 2019 | clinicaltrials |
| NCT03903458 | Tinostamustine and Nivolumab in Advanced Melanoma(ENIgMA) | unknown | Phase 1 | 21 | Markus JoergerOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03353402 | Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy | unknown | Phase 1 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02117362 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 1 | 8 | Providence Health & ServicesOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01191034 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 2 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | terminated | Phase 1 / Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | terminated | Phase 1 / Phase 2 | 19 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00223899 | A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma | completed | Phase 1 | 26 | VicalINDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT00470015 | Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00844064 | Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 | completed | Phase 1 | 62 | Isarna Therapeutics GmbHINDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02068079 | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 4 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01457131 | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02327390 | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma | terminated | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00527657 | Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients | completed | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00791271 | Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00568763 | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 11 | Mayo ClinicOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02115243 | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | completed | Phase 1 | 4 | Duke UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT01876641 | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib(ML28604) | terminated | Phase 1 | 18 | Mohammed M MilhemOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
| NCT01215500 | Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer | completed | Phase 1 | 63 | University of ChicagoOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2019source: clinicaltrials